Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tiaspirone in schizophrenia.

N C Moore, E Meyendorff, V Yeragani

    Journal of Clinical Psychopharmacology
    |April 1, 1987
    PubMed
    Summary

    Tiaspirone, a novel dopamine blocker, showed significant improvement in schizophrenic patients during a 28-day trial. This new antipsychotic medication was well-tolerated, with no serious adverse effects observed.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ultrathin thermoacoustic nanobridge loudspeakers from ALD on polyimide.

    Nanotechnology·2016
    Same author

    Manipulating walking path configuration influences gait variability and six-minute walk test outcomes in older and younger adults.

    Gait & posture·2016
    Same author

    Reduction of dyskinesias and psychiatric disability with clozapine over different time courses.

    Journal of psychopharmacology (Oxford, England)·2012
    Same author

    Neuroprotection for Parkinson's disease.

    Journal of neural transmission. Supplementum·2007
    Same author

    Tissue inhibitors of matrix metalloproteinases are elevated in cerebrospinal fluid of neurodegenerative diseases.

    Journal of the neurological sciences·2003
    Same author

    Tardive dyskinesia--diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service.

    Schizophrenia bulletin·2002

    Area of Science:

    • Psychiatry
    • Neuroscience
    • Pharmacology

    Background:

    • Schizophrenia is a complex mental disorder.
    • Current antipsychotic treatments can cause significant side effects.
    • Dopamine blockade is a key mechanism in antipsychotic action.

    Purpose of the Study:

    • To evaluate the efficacy and safety of tiaspirone in schizophrenic patients.
    • To determine the optimal dosage range for tiaspirone.
    • To assess the side effect profile, particularly extrapyramidal symptoms.

    Main Methods:

    • A single-blind, dose-ranging trial was conducted.
    • 14 patients with schizophrenia participated after a placebo washout.
    • Patients were treated for 28 days with tiaspirone.

    Main Results:

    • Significant improvements were observed in Global Assessment Scale (GAS), NOSIE, and Brief Psychiatric Rating Scale (BPRS) scores.
    • Tiaspirone was well-tolerated, with no serious adverse events.
    • Notably, 10 patients who previously experienced extrapyramidal symptoms on other neuroleptics did not experience them with tiaspirone.

    Conclusions:

    • Tiaspirone demonstrates efficacy in treating schizophrenia symptoms.
    • The compound appears to have a favorable safety profile, especially regarding extrapyramidal symptoms.
    • Tiaspirone may offer a promising alternative for schizophrenia treatment with reduced side effects.

    Related Experiment Videos